Allegra D extended release tablet that Aventis currently markets is the twice-daily Allegra D extended release tablets containing fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg.
Currently, 40 million adults and children are estimated to have recurring seasonal allergies with symptoms such as nasal congestion, runny nose, itchy throat and watery eyes. These symptoms usually occur in the seasons of spring and fall when large amounts of pollen are found in the air.
Allegra D extended release tablet are recommended twice daily. Allegra D extended release tablet acts swiftly, with nasal relief noticed within 1 hour after taking the medication. Allegra D extended release tablet could last up to 12 hours, peaking after two or three hours.
However, persons with kidney ailment and elderly persons are advised to take only one Allegra D extended release tablet daily. Allegra D extended release tablet should be taken without food and milk. One hour before meal is ideal.
Due to the decongestant (pseudoephedrine) component of Alelgra D extended release tablet, patients with severe heart (coronary artery) disease, angina, taking anti-depressants monoamine oxidase (MAO) inhibitor or have stopped taking MAO within 14 days, narrow-angle glaucoma and severe high blood pressure should stop or refrain from taking allegra D extended release tablet.
Caution should be exercised by those who have diabetes, thyroid disease, kidney problems especially urine retention and enlarged prostrate symptoms.
They should consult a physician before starting or stopping the use of Allegra D extended release tablet.
Side effects with Allegra D extended release tablets that maybe more likely to occur include headache, insomnia, and nausea. In extreme but rare and unlikely to occur cases such as convulsions, hallucinations and others. If you experience severe and prolong negative reactions with allegra D extended release tablet, stop taking allegra D and seek medical attention.
Aventis has currently applied for a new Allegra D extended release tablet. This Allegra D extended release tablet has just been submitted by Aventis as a new drug application (NDA) to the U.S. Food and Drug Administration (FDA). Allegra D extended release tablet is a 24-hour tablet containing 180mg of fexofenadine HCl and 240 mg of pseudophedrine HCl.
This is a once daily formulation used to treat seasonal allergy with nasal congestion such as hay fever and allergic rhinitis for adults and children 12 years and older.
The submission is seen as a move by Aventis to continue to improve and innovate with Allegra d extended release tablet and its commitment to help provide relief to millions of Americans plagued by seasonal allergies.